Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)

Inclusion Criteria: * All Groups: * Must not have a fever of ≥100.4° F on the day of vaccination * Any underlying chronic illness must be in stable condition * History of varicella or residence in a VZV-endemic area for ≥30 years * Group 1: * 70 years of age or older * Took part in the Shingles Prevention Study (SPS) (V211-004, NCT00007501) and received a single dose of Zoster Vaccine, Live ≥10 years prior to enrollment in this study * Group 2: * 70 years of age or older * Group 3: * 60 to 69 years of age * Group 4: * 50 to 59 years of age Exclusion Criteria: * All Groups: * History of hypersensitivity reaction to any vaccine component or an anaphylactic/anaphylactoid reaction to neomycin * Prior history of herpes zoster * Pregnant or breast-feeding, or expecting to conceive within the duration of the study * Has been treated with immunoglobulin or any blood products, other than autologous (self-donated) blood transfusion, in the 5 months prior to vaccination * Received any other vaccine within 4 weeks prevaccination * On immunosuppressive therapy * Has known or suspected immune dysfunction * Is taking any non-topical antiviral therapy with activity against herpesviruses, including, but not limited to acyclovir, famciclovir, valacyclovir, and ganciclovir. * Groups 2, 3, and 4: * Has previously received any varicella or zoster vaccine